The STIM1 trial, one of the first to investigate TFR feasibility, enrolled 100 chronic‐phase CML patients with sustained undetectable BCR::ABL1 transcripts (undetectable measurable residual disease, MRD) for at least 2 years on imatinib. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.